oxazoles has been researched along with gr 73632 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ball, RG; Bao, J; Bunda, J; Chicchi, G; Cook, J; DeVita, RJ; Doss, GA; Eng, W; Gantert, L; Hargreaves, R; Hora, DF; Jiang, J; Karanam, B; Kassick, AJ; Kumar, S; Lin, P; Lu, H; Madeira, M; Mills, SG; Purcell, M; Samuel, K; Tong, X; Tsao, KL; Tschirret-Guth, R; Wang, H; Wilson, D | 1 |
1 other study(ies) available for oxazoles and gr 73632
Article | Year |
---|---|
2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Glucuronides; Humans; Isoindoles; Metabolic Clearance Rate; Neurokinin-1 Receptor Antagonists; Oxazoles; Peptide Fragments; Substance P | 2013 |